Developing Next Generation Neuroactive Medicines to Treat Mental Illness
Lophora is a clinical-stage CNS drug discovery company developing novel, next-generation, neuroactive medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders.
Company
The company has identified and patented a new class of proprietary ligands. The lead compound LPH-5 is a highly selective small-molecule agonist of the Serotonin 5-HT2AR and exhibits robust CNS exposure, target engagement and efficacy in animal models of depression. LPH-5 has recently entered Phase I trials.
Lophora Announces First Subjects Dosed in Phase 1 Clinical Trial of LPH-5
Lophora ApS, a Danish biotech company focused on next-generation psychedelic therapies for central nervous system disorders, today announced that the
Lophora Successfully Completes $3M Financing to Propel Phase I Trials for Lead CNS Drug LPH-5
After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has
Lophora Receives Approval from EMA to Initiate Phase I Clinical Trial for LPH-5, a Promising Treatment for Depression.
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2AR therapeutics to treat psychiatric disorders, announced today that
Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5.
Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders,
People
Lophora is led by an experienced executive team with a strong scientific and commercial track record, backed by a board and advisors with decades of CNS drug development experience.
Request investor deck
Science & Pipeline
Lophora’s drug design platform is built on rational engineering of 5-HT2A agonists with optimized drug-like properties and reduced off-target activity.
LPH-5 is now in first-in-human evaluation, with LPH-48 and additional NCE candidates in expansion.
- Stage: Phase I initiated (LPH-5)
- Latest financing: $3M (Jan 2025)
- Lead asset: LPH-5 — selective 5-HT2A agonist
- Second asset: LPH-48 — pre-clinical fast-follower
- IP position: Composition of matter granted US/EU/CN/JP etc.
- Pipeline: Expandable NCE program targeting CNS indications
Investors
Lophora is funded by BII (Novo Nordisk Foundation), Innovation Fund Denmark, Export and Investment Fund of Denmark (EIFO), family offices and experienced biotech investors such as Don deBethizy (USA) and Tim Haines (UK).